Filtered By:
Drug: Taxotere

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 2210 results found since Jan 2013.

What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
Conclusion No study of high level of evidence is available to support any recommendation on sequential treatment for mCRPC. There are only clues that prospective clinical studies need to confirm.
Source: World Journal of Urology - September 15, 2015 Category: Urology & Nephrology Source Type: research

Trastuzumab-Associated Flagellate Erythema: Report in a Woman with Metastatic Breast Cancer and Review of Antineoplastic Therapy-Induced Flagellate Dermatoses
Conclusion Cutaneous adverse events to trastuzumab are uncommon. However, flagellate erythema should be added to the potential side effects of trastuzumab. In addition, trastuzumab should be added to the list of antineoplastic agents that may be associated with flagellate erythema.
Source: Dermatology and Therapy - October 27, 2015 Category: Dermatology Source Type: research

Vitamins in Pancreatic Cancer: A Review of Underlying Mechanisms and Future Applications
In this study, we performed a PubMed literature search to review the anticancer mechanisms and the preclinical and clinical studies that support the development of the bioactive vitamins A, C, D, E, and K in pancreatic cancer intervention. Preclinical studies have shown promising results for vitamin A in pancreatic cancer prevention, with clinical trials showing intriguing responses in combination with immunotherapy. For vitamin C, preclinical studies have shown slower tumor growth rates and/or increased survival when used alone or in combination with gemcitabine, with clinical trials with this combination revealing decrea...
Source: Advances in Nutrition - November 13, 2015 Category: Nutrition Authors: Davis-Yadley, A. H., Malafa, M. P. Tags: Reviews Source Type: research

The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review
Conclusions: HER2-directed therapies had an undeniable beneficial impact on the OS of patients with HER2+ mBC. The triple combination of docetaxel, pertuzumab and trastuzumab is associated with a survival extent of more than 4.5 years, compared with a life expectancy of 1.5 years achieved 14 years ago.
Source: Epidemiologic Perspectives and Innovations - November 17, 2015 Category: Epidemiology Authors: Diogo MendesCarlos AlvesNoémia AfonsoFátima CardosoJosé Passos-CoelhoLuís CostaSofia AndradeFrancisco Batel-Marques Source Type: research

The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer - a systematic review.
CONCLUSIONS: HER2-directed therapies had an undeniable beneficial impact on the OS of patients with HER2+ mBC. The triple combination of docetaxel, pertuzumab and trastuzumab is associated with a survival extent of more than 4.5 years, compared with a life expectancy of 1.5 years achieved 14 years ago. PMID: 26578067 [PubMed - as supplied by publisher]
Source: Clinical Genitourinary Cancer - November 19, 2015 Category: Cancer & Oncology Authors: Mendes D, Alves C, Afonso N, Cardoso F, Passos-Coelho JL, Costa L, Andrade S, Batel-Marques F Tags: Breast Cancer Res Source Type: research

NVP‐TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P‐glycoprotein (Pgp) function
CONCLUSIONS AND IMPLICATIONSThe application of NVP‐TAE684 to restore sensitivity of osteosarcoma MDR cells to the cytotoxic effects of chemotherapeutics will be useful for further study of Pgp‐mediated MDR in human cancer and may ultimately benefit cancer patients.
Source: British Journal of Pharmacology - November 1, 2015 Category: Drugs & Pharmacology Authors: Shunan Ye, Jianming Zhang, Jacson Shen, Yan Gao, Ying Li, Edwin Choy, Gregory Cote, David Harmon, Henry Mankin, Nathanael S Gray, Francis J Hornicek, Zhenfeng Duan Tags: RESEARCH PAPER Source Type: research

Abstract P1-13-03: Genome wide association study (GWAS) of genetic variants associated with docetaxel toxicity in the ROSE/TRIO-012 trial
Background: Genetic predisposition to docetaxel (Doc) toxicity contributes to unacceptable toxicity and reduced dose intensity, and may influence disease outcomes. We previously reported variants associated with Doc toxicity in candidate gene single nucleotide polymorphism (SNP) associations in a breast cancer treatment setting (Damaraju et al. Eur J Cancer (suppl); Vol 8 (7), page 175, 2010) and the identified variants were confirmed in an independent validation study (Damaraju et al, J Clin Oncol Vol 33, Issue 15 suppl, 2015: 540). Others have reported candidate SNP (Breast Cancer Res Treat, 2011 SWOG 0221 study) and GWA...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Damaraȷu, S., Gorbunova, V., Gelmon, K., Garcia–Saenz, J., Morales–Murillo, S., AbiGerges, D., Canon, J.–L., Kiselev, I., Cohen, G., Jerusalem, G., Thireau, F., Fresco, R., Houe, V., Press, M., Kumaran, M., Mackey, J. Tags: Poster Session Abstracts Source Type: research

Abstract P6-14-03: Genome wide association study (GWAS) to identify variants conferring ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
Background: In a candidate single nucleotide polymorphism (SNP) association study, we previously identified VEGFR-1 and VEGFR-2 SNPs strongly associated with treatment emergent hypertension (HT) in the ramucirumab (RAM) and docetaxel (Doc) arm in the ROSE/TRIO-012 study, a double-blinded multinational phase III trial that randomized 1,144 patients with advanced breast cancer to receive first-line Doc in combination with RAM or placebo (Mackey et al, JCO Jan 10, 2015:141-148; Mackey et al, JCO, Volume 33, Issue 15_suppl, May 20, 2015: 547). However, candidate SNP studies limit the number of genes for interrogation and a mor...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Mackey, J., Lipatov, O., Martin, M., Webster, M., Hegg, R., Verma, S., Ramos–Vazquez, M., Fresco, R., Thireau, F., Houe, V., Press, M., Kumaran, M., Damaraȷu, S. Tags: Poster Session Abstracts Source Type: research

Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer.
In this study, we first investigated the implication of the NPM1 and its Thr199 and Thr234/237 phosphorylated forms in PCa. We showed that phosphorylated forms of NPM1 interact with androgen receptor (AR) in nucleoplasm. N6L treatment of prostate tumor cells led to inhibition of NPM1 phosphorylation in conjunction with inhibition of AR activity. We also found that total and phosphorylated NPM1 were overexpressed in castration-resistant PCa. Assessment of the potential therapeutic role of N6L in PCa indicated that N6L inhibited tumor growth both in vitro and in vivo when used either alone or in combination with the standard...
Source: Oncotarget - March 21, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition REVIEW ARTICLE
Conclusion Level 1 evidence exists to support the use of nivolumab as second-line treatment of patients with squamous advanced NSCLC, as well as in select patients with nonsquamous disease. Benefits remain unknown in patients with targetable driver mutations, and use of PD-L1 expression to guide therapy remains controversial. Results from ongoing randomized trials evaluating biomarkers and other checkpoint inhibitors will further our understanding of this rapidly evolving area of oncology.
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Melosky, Chu, Juergens, Leighl, McLeod, Hirsh Tags: Chemotherapy, Basic Science, Pathology, Lung, Immunology/Immunobiology REVIEW ARTICLE Source Type: research

Anti-tumour activity of platinum compounds in advanced prostate cancer--a systematic literature review
Conclusion Platinum compounds have moderate anti-tumour activity in molecularly unselected patients with advanced prostate cancer. Translational evidence of DNA repair deficiency should be leveraged in future studies to select prostate cancer patients most likely to benefit from platinum-based therapy.
Source: Annals of Oncology - May 24, 2016 Category: Cancer & Oncology Authors: Hager, S., Ackermann, C. J., Joerger, M., Gillessen, S., Omlin, A. Tags: reviews Source Type: research

Overview of the Formulations and Analogs in the Taxanes' Story.
Abstract Taxanes are a family of diterpenes produced by the yews (Taxus genus) that are extensively used in chemotherapy. The family encompasses paclitaxel, docetaxel and the recently added cabazitaxel, all of which were proven to be promising anti-cancer drugs. Due to the over harvesting danger threatening the yew trees as well as the many challenges faced by taxane-based chemotherapy, new formulations, analogs and delivery systems are required. Here, we undertook a structured search of the bibliographical database PubMed for peer-reviewed research papers relying on key words and date of publication and organized...
Source: Current Medicinal Chemistry - September 6, 2016 Category: Chemistry Authors: Yassine F, Gali-Muhtasib H, Salibi E Tags: Curr Med Chem Source Type: research

The safety and efficacy of ramucirumab in combination with docetaxel in the treatment of lung cancer.
This article has for objective to summarize efficacy and safety data of the use of ramucirumab in combination with docetaxel in second line in NSCLC. Expert commentary: REVEL constitutes the first significant advance in second-line setting for patients eligible to anti-angiogenic therapy. The landscape of post-platinum therapy in NSCLC is considerably evolving and the role of ramucirumab or other anti-angiogenic agents as nintedanib in this setting has to be discussed for each patient with other available treatment options, among which immune checkpoints inhibitors, as well as the best treatment sequence. PMID: 2768651...
Source: Expert Review of Anticancer Therapy - October 1, 2016 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Understanding the role of new systemic agents in the treatment of prostate cancer
ConclusionThe increasing number of high‐quality clinical trials, with overlapping patient populations has made defining the correct therapy for men with mPC challenging for urologists and medical oncologists. The data suggests that the optimal sequence of drugs is not only unknown but also not necessarily the same for each patient. As such, we suggest a more individualized approach to the treatment of prostate cancer depending on patient and disease factors.
Source: BJU International - October 5, 2016 Category: Urology & Nephrology Authors: Julia Corfield, Jack Crozier, Anthony Joshua, Damien Bolton, Nathan Lawrentschuck Tags: Supplement Article Source Type: research

Immunotherapy in Lung Cancer
The treatment of patients with good performance status and advanced stage non –small cell lung cancer has been based on the use of first-line platinum-based doublet and second-line docetaxel. Immunotherapy represents a new therapeutic approach with the potential for prolonged benefit. Although the vaccines studied have not shown benefit in patients with non–small cell lun g cancer, immune checkpoint inhibitors against the PD-1/PD-L1 axis showed increased overall survival compared with docetaxel in randomized clinical trials, which led to the approval of nivolumab and pembrolizumab. Because only a minority of patients b...
Source: Hematology/Oncology Clinics of North America - November 30, 2016 Category: Cancer & Oncology Authors: Lingling Du, Roy S. Herbst, Daniel Morgensztern Source Type: research